Due to its rich research environment – the campus is home to the Fraunhofer Institute for Microstructure of Materials and Systems (IMWS), the Helmholtz Centre for Environmental Research, the Leibniz Institute of Plant Biochemistry and the Max Planck Institute of Microstructure Physics – it has become a prime location for both domestic and foreign companies, including Heppe Medical Chitosan (HMC+) and RGCC Central Europe, a division of Swiss medical genetics company RGCC Group.
“We are in a particularly advantageous situation thanks to the compact nature of the Weinberg Campus, which means we are near to both the university and the research institutes,” says Katja Richter, managing director of HMC+, which produces a type of biopolymer derived from the shells of crustaceans. “This facilitates productive collaboration and helps us to find new partners.”
Resident firms also include Vivoryon Therapeutics, which develops treatments for Alzheimer’s disease. The company’s investors include a Danish consortium led by Dr. Claus Christiansen, chairman of Denmark’s Nordic Bioscience. Vivoryon is currently partnering with Nordic Bioscience on the development of its PQ912 therapy for Alzheimer’s.